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Clozapine and Smoking
One of your patients has come into the pharmacy to collect their medication. You 
see they are also eligible for a medicines use review and the patient consents for 
this. Before you go in the consultation room, you look on their records and see the 
following regular prescriptions:
 Bisoprolol 1.25mg – once daily
 Sertraline 100mg – once daily
During the medicines use review you ask if the patient buys or uses any other 
medicines, herbal medicines or any other alternatives medicines.
“I do get my Clozaril® from the clinic”
At the end of the review, you ask if they would like any health living advice. 
“I have been thinking about stopping smoking recently, could you give me some 
advice and is it possible to buy something today?”
Why is there no record of Clozaril® on the patient medication record?
Clozaril®, a brand of clozapine, is an atypical antipsychotic licensed for the patient 
with treatment resistant schizophrenia, those intolerant of other antipsychotic 
psychosis in Parkinson's disease (Joint Formulary Committee, 2016). Clozapine is a 
restricted drug and requires specialist supervision and the patient, prescriber, 
pharmacist and pharmacy require to be registered with a clozapine monitoring 
service (Novartis Pharmaceuticals UK Ltd, 2016). Although rare, clozapine has a life 
threatening, adverse effect; agranulocytosis – which is a lowering of granulocytes (a 
class of white blood cells) to an extent where there is increased risk of an acquiring 
an infection as the patient becomes immunocompromised. Therefore it is most likely 
that clozapine is prescribed by a psychiatrist and dispensed by a different pharmacy.
What actions can you take to ensure this information is in available in the 
future?
Clozapine could be added on the notes section on the pharmacy medication record. 
This will allow you, in future, to prepare for medicines use reviews and check if there 
is an interaction when there is a new medication prescribed. One of the 
recommendations as part of the medicines use review is to ask the GP to ensure 
clozapine is listed on their system (as an hospital item) so interactions may appear 
here also and appear on the Summary Care Record for other healthcare 
professionals to view.
What healthy living advice would you provide for a patient taking clozapine?
Clozapine can cause weight gain and can cause impaired glucose tolerance and 
cause or exacerbate diabetes mellitus (Novartis Pharmaceuticals UK Ltd (2016). 
Therefore, tailored advice should include healthy eating and regular exercise. 
Clozapine also has anti-cholinergic side effects and can cause constipation, which 
can be severe and there have been reports of fatal gastrointestinal obstruction. To 
prevent this, along with the above advice, the patient should be advised to eat fruit 
and vegetables and food with a high fibre content and adequate fluid intake.
Should you supply a smoking cessation product to the patient?
There is a significant pharmacokinetic interaction between the hydrocarbons in 
smoking and clozapine (Smith, Mican and Ellingrod, 2014). Clozapine is metabolised
mainly by the cytochrome P450 enzyme, CYP1A2, which is induced by the 
hydrocarbons. Therefore, a higher clozapine dose is required to achieve a similar 
clozapine plasma level to a non-smoker. When the patient reduces their smoking, 
the intensity of this interaction will reduce, and the dose of clozapine will need to 
decrease. If not, the plasma levels of clozapine will accumulate and the patient is at 
risk of increased adverse events. 
The patient should be referred to the mental health team so that they can be 
managed during the smoking cessation period. During this time, the dose would be 
carefully reduced whilst monitoring the patients’ presentation and plasma 
concentration of clozapine. However as a community pharmacist, you can offer 
support to the patient during this time.
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